Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00050505 · ClinicalTrials.gov registry record · Phase 2
Expanded Dryvax Dilution Study in Previously Vaccinated Adults
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 927
- Enrollment target
NCT00050505: Completed Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00050505 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 927 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (597% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00050505, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 927 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and effect of diluting smallpox vaccine, making a larger number of doses in case smallpox is released into the environment. A total of up to 927 healthy adults between the ages of 32 and 70 years who were already vaccinated against smallpox (but not since 1989) will volunteer for this study for up to 34 weeks and receive different strengths of vaccine. Some subjects may participate for longer if they choose to be revaccinated because the first vaccination does not take. The vaccine will be given by making small cuts in the skin and putting the vaccine into these cuts. After the screening visit, volunteers will be followed through study visits and follow up phone calls. Blood will be collected during some study visits to look at the immune system (body system that fights infection) response.
Interventions
- BIOLOGICAL Live vaccinia virus vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 927 participants |
| Start Date | 2002-10 |
| Est. Completion | 2003-12 |
| Phase | Phase 2 |
What the finished NCT00050505 record still lists
NCT00050505 is an interventional study that assigns participants to a tested intervention. The registered 927 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (597% higher).
The record links to 0 conditions, and to 1 intervention - of which Live vaccinia virus vaccine is the first listed.
NCT00050505 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00050505 about?
NCT00050505 is a clinical study titled "Expanded Dryvax Dilution Study in Previously Vaccinated Adults". The purpose of this study is to determine the safety and effect of diluting smallpox vaccine, making a larger number of doses in case smallpox is released into the environment. A total of up to 927 healthy adults between the ages of 32 and 70 years who were already vaccinated against smallpox (but n...
What is the current status of trial NCT00050505?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 927 participants. The study started on 2002-10. Estimated completion is 2003-12.
What interventions are being tested in trial NCT00050505?
The interventions under investigation include: Live vaccinia virus vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00050505?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00050505's enrollment target sits among peer trials
927 29th of 2000 higher than 1,972 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06378541 · 928 participants · NA
Smartphone App Enhanced Facilitation Among Veterans in a Mental Health Inpatient Setting (Project HOPE)
- NCT06555029 · 929 participants · NA
Oral Health Intervention in Adult Primary Care
- NCT03995082 · 925 participants · NA
Breast Cancer Patient Engagement With Patient Reported Outcome Measure Survey
- NCT05216432 · 930 participants · Phase 1
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia